ES2094688A1 - Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. - Google Patents

Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.

Info

Publication number
ES2094688A1
ES2094688A1 ES09401784A ES9401784A ES2094688A1 ES 2094688 A1 ES2094688 A1 ES 2094688A1 ES 09401784 A ES09401784 A ES 09401784A ES 9401784 A ES9401784 A ES 9401784A ES 2094688 A1 ES2094688 A1 ES 2094688A1
Authority
ES
Spain
Prior art keywords
oil
organic
nanoemulsion
agent
ophthalmic vehicle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES09401784A
Other languages
English (en)
Other versions
ES2094688B1 (es
Inventor
Dachs Anna Coll
Perdiguer Nuria Carreras
Valdivia Javier Galan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Cusi SA
Original Assignee
Laboratorios Cusi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Cusi SA filed Critical Laboratorios Cusi SA
Priority to ES09401784A priority Critical patent/ES2094688B1/es
Priority to DE69531179T priority patent/DE69531179T2/de
Priority to EP95202053A priority patent/EP0696452B1/en
Priority to AT95202053T priority patent/ATE243995T1/de
Priority to US08/509,746 priority patent/US5698219A/en
Priority to JP7200760A priority patent/JP2960867B2/ja
Publication of ES2094688A1 publication Critical patent/ES2094688A1/es
Application granted granted Critical
Publication of ES2094688B1 publication Critical patent/ES2094688B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

NANOEMULSION DEL TIPO DE ACEITE EN AGUA, UTIL COMO VEHICULO OFTALMICO Y PROCEDIMIENTO PARA SU PREPARACION. LA NANOEMULSION COMPRENDE 0,1-10 POR CIENTO (P/V) DE UN ACEITE; 0,1-10 POR CIENTO (P/V) DE UN TENSIOACTIVO NO IONICO; COMO MAXIMO 0,01 POR CIENTO (P/V) DE CLORURO DE BENZALCONIO; UN FARMACO O UN PRECURSOR O SUSTANCIA ACTIVA; Y OPCIONALMENTE, UNO O VARIOS DE LOS SIGUIENTES COMPONENTES: UN AGENTE ISOTONIZANTE, VISCOSIZANTE O ESTABILIZANTE, UN TAMPON Y/O UN ANTIOXIDANTE EN PROPORCIONES VARIABLES. EL PROCEDIMIENTO COMPRENDE: (A) PREPARAR UNA FASE ACUOSA CONTENIENDO, ENTRE OTROS, UN TENSIOACTIVO NO IONICO; (B) PREPARAR UNA FASE ORGANICA CONTENIENDO DISUELTOS UN ACEITE Y UNA SUSTANCIA ACTIVA EN UN DISOLVENTE ORGANICO MISCIBLE EN AGUA EN TODAS PROPORCIONES; (C) INCORPORAR LA FASE ORGANICA SOBRE LA ACUOSA BAZO MODERADA AGITACION; Y (D) EVAPORAR TOTALMENTE EL DISOLVENTE ORGANICO Y PARTE DEL AGUA HASTA EL VOLUMEN FINAL DESEADO. IMPORTANTES APLICACIONES COMO VEHICULO OFTALMICO EN PREPARADOS DESTINADOS AL TRATAMIENTO DE LOS TRASTORNOS Y ENFERMEDADES OCULARES.
ES09401784A 1994-08-08 1994-08-08 Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. Expired - Fee Related ES2094688B1 (es)

Priority Applications (6)

Application Number Priority Date Filing Date Title
ES09401784A ES2094688B1 (es) 1994-08-08 1994-08-08 Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
DE69531179T DE69531179T2 (de) 1994-08-08 1995-07-26 Nanoemulsion von dem Öl-in-Wasser Typ, gebrauchbar als ein ophthalmischen Vehikel und Verfahren zur seiner Herstellung
EP95202053A EP0696452B1 (en) 1994-08-08 1995-07-26 Nanoemulsion of the oil in water type, useful as an ophthalmic vehicle and process for the preparation thereof
AT95202053T ATE243995T1 (de) 1994-08-08 1995-07-26 Nanoemulsion von dem öl-in-wasser typ, gebrauchbar als ein ophthalmischen vehikel und verfahren zur seiner herstellung
US08/509,746 US5698219A (en) 1994-08-08 1995-07-31 Nanoemulsion of the oil water type, useful as an ophthalmic vehicle and process for the preparation thereof
JP7200760A JP2960867B2 (ja) 1994-08-08 1995-08-07 眼科用ビヒクルとして有用な水中油型ナノエマルジョンおよびその調製法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES09401784A ES2094688B1 (es) 1994-08-08 1994-08-08 Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.

Publications (2)

Publication Number Publication Date
ES2094688A1 true ES2094688A1 (es) 1997-01-16
ES2094688B1 ES2094688B1 (es) 1997-08-01

Family

ID=8287242

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09401784A Expired - Fee Related ES2094688B1 (es) 1994-08-08 1994-08-08 Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.

Country Status (6)

Country Link
US (1) US5698219A (es)
EP (1) EP0696452B1 (es)
JP (1) JP2960867B2 (es)
AT (1) ATE243995T1 (es)
DE (1) DE69531179T2 (es)
ES (1) ES2094688B1 (es)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA966579B (en) * 1995-08-04 1998-02-02 Wakamoto Pharma Co Ltd O/W emulsion composition for eye drops.
ES2118033B1 (es) * 1996-02-16 1999-07-01 Bial Ind Farmaceutica S A Formulacion farmaceutica antiinflamatoria.
US6534070B1 (en) 1997-11-19 2003-03-18 Schering Aktiengesellschaft Composition with azelaic acid
DE19810655A1 (de) * 1998-03-12 1999-09-16 Univ Eberhard Karls Arzneimittel mit einem Gehalt an Ciclosporin
EP1104290B1 (en) * 1998-08-13 2010-03-31 Cima Labs Inc. Microemulsions as solid dosage forms for oral administration
AU5405399A (en) * 1998-09-14 2000-04-03 Vesifact Ag Utilization of nanocells in final culture medium products
GB9823246D0 (en) * 1998-10-24 1998-12-16 Danbiosyst Uk A nasal drug delivery composition
FR2787027B1 (fr) * 1998-12-14 2001-01-12 Oreal Nanoemulsion a base d'esters gras de sucre ou d'ethers gras de sucre et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787325B1 (fr) * 1998-12-17 2001-01-26 Oreal Nanoemulsion a base d'esters gras de sorbitan oxyethylenes ou non oxyethylenes, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787326B1 (fr) † 1998-12-17 2001-01-26 Oreal Nanoemulsion a base d'esters gras de glycerol, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2788007B1 (fr) * 1999-01-05 2001-02-09 Oreal Nanoemulsion a base de copolymeres blocs d'oxyde d'ethylene et d'oxyde de propylene, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
WO2000064528A1 (en) 1999-04-28 2000-11-02 Situs Corporation Drug delivery system
US8236335B2 (en) * 1999-04-28 2012-08-07 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
US7767216B2 (en) * 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
US7655252B2 (en) * 1999-04-28 2010-02-02 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
FR2811564B1 (fr) 2000-07-13 2002-12-27 Oreal Nanoemulsion contenant des polymeres non ioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
JP2002154989A (ja) * 2000-11-14 2002-05-28 Lion Corp 眼科用組成物、及び生体粘膜への薬物の滞留性向上組成物
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
SI1534286T1 (sl) 2002-07-29 2010-04-30 Rigel Pharmaceuticals Inc Postopki za zdravljenje ali prepreŽŤevanje avtoimunskih bolezni z 2,4-pirimidindiaminskimi spojinami
US8802116B2 (en) * 2003-02-27 2014-08-12 Novasel Australia Pty. Ltd. Poloxamer emulsion preparations
AU2003900887A0 (en) * 2003-02-27 2003-03-13 Novasel Australia Pty Ltd Poloxamer emulsion preparations
ES2365223T3 (es) 2003-08-07 2011-09-26 Rigel Pharmaceuticals, Inc. Compuestos 2,4-pirimidindiamínicos y usos como agentes antiproliferativos.
EP1688169A4 (en) * 2003-11-28 2008-10-01 Mitsubishi Chem Corp METHOD FOR PRODUCING FINE PARTICLES OF AN ORGANIC COMPOUND
US8449867B2 (en) 2004-08-31 2013-05-28 Stiefel Research Australia Pty Ltd Microemulsion and sub-micron emulsion process and compositions
ES2429040T5 (es) * 2004-08-31 2017-06-13 Stiefel Research Australia Pty Ltd Método y composiciones de microemulsión y emulsión submicrónica
DE602004017477D1 (de) 2004-11-09 2008-12-11 Novagali Pharma Sa Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential
AU2005304034B2 (en) * 2004-11-09 2012-02-16 Santen Sas Ophthalmic emulsions containing an immunosuppressive agent
US20080145430A1 (en) * 2004-12-08 2008-06-19 Santipharp Panmai Ophthalmic Nanoparticulate Formulation Of A Cyclooxygenase-2 Selective Inhibitor
WO2007000842A1 (ja) * 2005-06-29 2007-01-04 Mitsubishi Chemical Corporation 粒状物分散組成物及びその製造方法、並びに、粒状物及び医薬品
WO2008051186A2 (en) * 2005-08-09 2008-05-02 Nanobio Corporation Nanoemulsion containing compositions having ant i -inflammatory activity
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
EP1991532B1 (en) 2006-02-24 2017-01-11 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US11311477B2 (en) 2006-03-07 2022-04-26 Sgn Nanopharma Inc. Ophthalmic preparations
US10137083B2 (en) 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
WO2007103294A2 (en) * 2006-03-07 2007-09-13 Novavax, Inc. Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same
EP2319517B1 (en) 2006-06-01 2013-09-11 Novagali Pharma S.A. Use of prodrugs for ocular intravitreous administration
WO2008035246A2 (en) 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
ES2380551T3 (es) 2006-11-21 2012-05-16 Rigel Pharmaceuticals, Inc. Sales de profármaco de compuestos de 2,4-pirimidindiamina y sus usos
AU2007329579A1 (en) 2006-12-01 2008-06-12 Anterios, Inc. Amphiphilic entity nanoparticles
CA2672973C (en) 2006-12-21 2016-03-08 Novagali Pharma Sa Process for manufacturing ophthalmic oil-in-water emulsions
US8145673B2 (en) * 2007-02-16 2012-03-27 Microsoft Corporation Easily queriable software repositories
US20080201330A1 (en) * 2007-02-16 2008-08-21 Microsoft Corporation Software repositories
EP1985298A1 (en) * 2007-04-24 2008-10-29 Azad Pharma AG Ophtalmic oil-in-water emulsions containing prostaglandins
US8747872B2 (en) 2007-05-02 2014-06-10 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
EP2016936B1 (en) * 2007-07-09 2010-09-15 Novagali Pharma S.A. Oil in water emulsion comprising NSAIDs and quaternary ammonium halides
WO2009007409A2 (en) * 2007-07-09 2009-01-15 Novagali Pharma Sa Oil in water emulsion comprising nsaids and quaternary ammonium halides
US8512687B2 (en) 2007-07-09 2013-08-20 Novagali Pharma Sa Oil in water emulsion comprising NSAIDs and quaternary ammonium halides
AU2008310956B2 (en) 2007-10-08 2014-08-07 Aurinia Pharmaceuticals Inc. Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
CA2706517C (en) * 2007-11-28 2015-11-17 Commonwealth Scientific And Industrial Research Organisation Nanoemulsion as delivery vehicles for active components
KR101805116B1 (ko) * 2007-12-04 2017-12-06 산텐 에스에이에스 덱사메타손 팔미테이트와 같은 코르티코스테로이드 전구약물을 포함하는 안과질환 치료용 조성물
EP2234608A2 (en) 2007-12-11 2010-10-06 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
EP2271314A4 (en) * 2008-03-28 2013-12-25 Univ Massachusetts COMPOSITIONS AND METHODS FOR PREPARING NANOEMULSIONS
AU2009260572B2 (en) * 2008-05-28 2015-07-23 Alcon Research, Ltd. Self-preserved emulsions
WO2010057197A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
WO2010078369A2 (en) 2008-12-30 2010-07-08 Rigel Pharmaceuticals, Inc. Pyrimidinediamine kinase inhibitors
NZ594323A (en) 2009-01-23 2013-05-31 Rigel Pharmaceuticals Inc Compositions and methods for inhibition of the jak pathway
CN102405044A (zh) 2009-02-06 2012-04-04 南加利福尼亚大学 含有单萜的治疗组合物
CA2751612A1 (en) 2009-02-06 2010-08-12 The Regents Of The University Of California Calcium-binding agents induce hair growth and/or nail growth
EP2228058A1 (en) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
CN102458370A (zh) 2009-06-09 2012-05-16 卢克斯生物科技公司 用于眼科用途的表面药物递送系统
EP2459195A1 (en) 2009-07-28 2012-06-06 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP2394636B1 (en) * 2010-05-28 2014-03-19 Novagali Pharma S.A. Method for treating retinal conditions using an intraocular tamponade
EP2389939A1 (en) 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
WO2011103514A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha triglyceride emulsions
WO2011103510A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha ester emulsions
US20110200645A1 (en) * 2010-02-18 2011-08-18 Martek Biosciences Corporation DHA Free Fatty Acid Emulsions
CN102892289B (zh) 2010-03-03 2015-03-25 尼昂克技术公司 包含单萜的药物组合物
RS55010B1 (sr) 2010-04-24 2016-11-30 Viamet Pharmaceuticals Inc Jedinjenja koja inhibiraju metaloencime
KR101937495B1 (ko) 2010-07-28 2019-01-10 리겔 파마슈티칼스, 인크. Ｊａｋ 경로의 억제를 위한 조성물 및 방법
EP2883543B1 (en) 2010-08-27 2016-11-16 Neonc Technologies Inc. Pharmaceutical compositions comprising perillyl alcohol carbamates
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
CA2816088A1 (en) 2010-10-28 2012-05-03 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
US8389543B2 (en) 2010-11-13 2013-03-05 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
JP6030565B2 (ja) * 2010-12-10 2016-11-24 エヌエス テクノロジーズ プロプライエタリー リミテッドＮｓ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｐｔｙ Ｌｔｄ ミニエマルション、同ミニエマルションを形成するための方法および医薬品の製造における同ミニエマルションの使用
BR112013014484A2 (pt) 2010-12-13 2016-07-19 Viamet Pharmaceuticals Inc compostos inibidores de metaloenzimas
BR112013015107B1 (pt) 2010-12-17 2022-03-22 Neonc Technologies Inc. Composição farmacêutica, uso de um álcool isoperílico ou um carbamato de álcool isoper ílico e processo para produzir um carbamato de álcool isoperílico
EP2678297A2 (en) 2011-02-25 2014-01-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Chrysophaentin analogs that inhibit ftsz protein
WO2012149416A2 (en) 2011-04-28 2012-11-01 University Of Southern California Human myeloid derived suppressor cell cancer markers
EA024789B1 (ru) 2011-06-19 2016-10-31 Ваймет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
KR101912850B1 (ko) 2011-06-19 2018-10-30 비아멧 파마슈티컬즈(엔씨), 인코포레이티드 금속효소 억제제 화합물
EP2723730A4 (en) 2011-06-23 2014-12-31 Viamet Pharmaceuticals Inc METALLOENZYMHEMMERVERBINDUNGEN
EP2567689A1 (en) 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
EP2788343B1 (en) 2011-12-11 2018-02-28 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
KR102009698B1 (ko) 2011-12-20 2019-08-13 바이옴 테라퓨틱스 리미티드 진균 감염의 치료를 위한 국소 오일 조성물
BR112014017751B1 (pt) 2012-01-20 2021-12-07 Mycovia Pharmaceuticals, Inc Compostos inibidores de metaloenzima, composições compreendendo os ditos compostos e uso dos ditos compostos
US9278132B2 (en) * 2012-02-13 2016-03-08 Bausch & Lomb Incorporated Ophthalmic pharmaceutical compositions and methods of making and using same
CN106902108B (zh) 2012-03-19 2020-07-21 巴克老龄化研究所 App特异性bace抑制剂(asbi)及其用途
EP2828241B1 (en) 2012-03-23 2018-09-12 Mateon Therapeutics, Inc. Compositions and methods for inhibition of cathepsins
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
CN104995176B (zh) 2013-02-12 2019-02-22 巴克老龄化研究所 调节bace所介导的app加工的乙内酰脲
JP6589086B2 (ja) * 2013-04-12 2019-10-16 ビョーメ セラピューティクス リミテッド 抗菌薬の組成物および製剤、その製造法および微生物感染症の治療方法
JP2014028865A (ja) * 2013-11-11 2014-02-13 Santen Sas 眼科用水中油型乳剤を製造する方法
CA2939660A1 (en) * 2014-02-14 2015-08-20 Jingjun Huang Compositions of nanoemulsion delivery systems
WO2015186040A1 (en) * 2014-06-02 2015-12-10 Sun Pharmaceutical Industries Limited Stable nanoemulsion composition
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
WO2016130800A2 (en) 2015-02-12 2016-08-18 Neonc Technologies Inc. Pharmaceutical compositions comprising perillyl alcohol derivatives
US10065946B2 (en) 2015-08-04 2018-09-04 Rigel Pharmaceuticals, Inc. Benzazole compounds and methods for making and using the compounds
EP3397629B1 (en) 2015-12-30 2023-04-19 NQP 1598, Ltd. Metalloenzyme inhibitor compounds
US10710983B2 (en) 2016-06-27 2020-07-14 Rigel Pharmaceuticals, Inc. 2,4-diamino-pyrimidine compounds and method for making and using the compounds
CA3032695C (en) * 2016-08-19 2021-11-23 Akrivista, LLC Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
EP3532465B1 (en) 2016-10-26 2023-03-01 Rigel Pharmaceuticals, Inc. Pyrazole amide compounds as irak inhibitors
EP3532470B1 (en) 2016-10-26 2022-12-07 Rigel Pharmaceuticals, Inc. Oxazole derivatives for use as irak inhibitors and method for their preparation
JP2019535829A (ja) 2016-11-21 2019-12-12 エイリオン セラピューティクス， インコーポレイテッド 大型薬剤の経皮送達
EP3547836A4 (en) 2016-11-30 2020-08-05 Neonc Technologies Inc. PERILLYL ALCOHOL-3 BROMOPYRUVATE CONJUGATE AND METHOD OF TREATMENT OF CANCER
WO2018125799A2 (en) 2016-12-29 2018-07-05 Viamet Pharmaceuticals (Bermuda), Ltd. Metalloenzyme inhibitor compounds
EP4311577A3 (en) 2016-12-29 2024-04-17 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
JP7183164B2 (ja) 2017-01-05 2022-12-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｐａｃ１受容体作動薬（ｍａｘｃａｐ）及びその用途
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
CN111032642B (zh) 2017-06-29 2023-07-18 里格尔药品股份有限公司 激酶抑制剂及制造和使用方法
CN114376961A (zh) 2017-08-18 2022-04-22 阿克里维斯塔有限责任公司 诊断和治疗干眼综合症的方法和用于治疗人类眼睛的组合物
US11414450B1 (en) 2017-08-28 2022-08-16 Revagenix, Inc. Aminoglycosides and uses thereof
US20210292410A1 (en) 2017-12-07 2021-09-23 Morphosys Ag Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
WO2019157195A1 (en) 2018-02-08 2019-08-15 Neonc Technologies, Inc Methods of permeabilizing the blood brain barrier
WO2019194858A1 (en) 2018-04-03 2019-10-10 Achaogen, Inc. Modular synthesis of aminoglycosides
BR112020022420A2 (pt) 2018-05-03 2021-03-02 Rigel Pharmaceuticals, Inc. composto, composição farmacêutica, método, método para tratar uma doença em um indivíduo e método para produzir o composto
SG11202010913PA (en) 2018-05-03 2020-12-30 Rigel Pharmaceuticals Inc Rip1 inhibitory compounds and methods for making and using the same
WO2020047197A1 (en) * 2018-08-29 2020-03-05 Ocugen, Inc. Ophthalmic compositions and methods of use
WO2020092845A1 (en) 2018-11-01 2020-05-07 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
EA202191983A1 (ru) 2019-01-22 2021-12-01 Аеовиан Фармасьютикалз, Инк. МОДУЛЯТОРЫ mTORC И ИХ ПРИМЕНЕНИЕ
US20200377518A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
GB201909358D0 (en) * 2019-06-28 2019-08-14 Smoukov Stoyan K Oil-in-water emulsion of nano-sized self-emulsified particulates
CA3147443A1 (en) 2019-08-08 2021-02-11 Rigel Pharmaceuticals, Inc. Compounds and method for treating cytokine release syndrome
ES2970382T3 (es) 2019-08-14 2024-05-28 Rigel Pharmaceuticals Inc Método para bloquear o mejorar el síndrome de liberación de citocinas
AR119857A1 (es) 2019-08-30 2022-01-19 Rigel Pharmaceuticals Inc Compuestos de pirazol, formulaciones de los mismos y su uso para la inhibición de una proteína irak
CN115279763A (zh) 2019-09-06 2022-11-01 里格尔药品股份有限公司 Rip1抑制化合物以及制备和使用所述化合物的方法
TW202122397A (zh) 2019-09-06 2021-06-16 美商雷傑製藥公司 Ｒｉｐ１抑制性化合物及用於製備和使用其之方法
TW202132307A (zh) 2019-11-07 2021-09-01 美商雷傑製藥公司 雜環ｒｉｐ１抑制性化合物
WO2022187303A1 (en) 2021-03-03 2022-09-09 Rigel Pharmaceuticals, Inc. A method for treating a disease or condition using a pyrazole compound or formulation thereof
TW202300490A (zh) 2021-03-11 2023-01-01 美商雷傑製藥公司 雜環rip1激酶抑制劑
PL438501A1 (pl) * 2021-07-16 2023-01-23 Uniwersytet Medyczny Im.Piastów Śląskich We Wrocławiu Kompozycja w postaci nanoemulsji na bazie oleju roślinnego, kompozycja wielofazowa oraz sposób wytwarzania tych kompozycji
WO2023166488A1 (en) 2022-03-04 2023-09-07 Revagenix, Inc. Broad spectrum aminoglycosides and uses thereof
WO2023183377A1 (en) 2022-03-23 2023-09-28 Rigel Pharmaceuticals, Inc. Pyrimid-2-yl-pyrazole compounds as irak inhibitors
WO2023192479A1 (en) 2022-03-31 2023-10-05 Rigel Pharmaceuticals, Inc. Tricyclic irak inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0253472A1 (en) * 1986-05-16 1988-01-20 Green Cross Corporation Ophthalmic flurbiprofen preparation
EP0279241A1 (en) * 1987-01-28 1988-08-24 Warner-Lambert Company Stabilized ophthalmic compositions
EP0480690A1 (en) * 1990-10-10 1992-04-15 Ciba-Geigy Ag Aqueous ophthalmic microemulsions of tepoxalin
WO1994005298A1 (en) * 1992-08-28 1994-03-17 Pharmos Corporation Submicron emulsions as ocular drug delivery vehicles

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2832721A (en) * 1956-07-23 1958-04-29 Merck & Co Inc Vitamin emulsions
JPH0647533B2 (ja) * 1984-08-10 1994-06-22 裕 水島 ４−ビフエニリル酢酸系化合物含有脂肪乳剤
US5171566A (en) 1986-05-16 1992-12-15 The Green Cross Corporation Flurbiprofen derivative ophthalmic preparation
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
JPH06511419A (ja) * 1990-06-08 1994-12-22 アフィニティー　バイオテック，インコーポレイテッド ミクロエマルジョンを製造する方法
IL98747A0 (en) 1991-07-05 1992-07-15 Yissum Res Dev Co Ophthalmic compositions
IL101007A (en) * 1992-02-18 1997-08-14 Pharmos Ltd Dry stable compositions prepared by lyophilization

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0253472A1 (en) * 1986-05-16 1988-01-20 Green Cross Corporation Ophthalmic flurbiprofen preparation
EP0279241A1 (en) * 1987-01-28 1988-08-24 Warner-Lambert Company Stabilized ophthalmic compositions
EP0480690A1 (en) * 1990-10-10 1992-04-15 Ciba-Geigy Ag Aqueous ophthalmic microemulsions of tepoxalin
WO1994005298A1 (en) * 1992-08-28 1994-03-17 Pharmos Corporation Submicron emulsions as ocular drug delivery vehicles

Also Published As

Publication number Publication date
US5698219A (en) 1997-12-16
DE69531179T2 (de) 2004-04-15
EP0696452A1 (en) 1996-02-14
JP2960867B2 (ja) 1999-10-12
ATE243995T1 (de) 2003-07-15
ES2094688B1 (es) 1997-08-01
EP0696452B1 (en) 2003-07-02
DE69531179D1 (de) 2003-08-07
JPH0899867A (ja) 1996-04-16

Similar Documents

Publication Publication Date Title
ES2094688A1 (es) Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
EP0326196B1 (en) Aqueous pharmaceutical preparation
DE69327491T2 (de) Verfahren zum Herstellen von Microkugeln für die verzögerte Verabreichung des LHRH-Hormons und dessen Analoga, Microkugeln und so erhaltene Zusammensetzungen
KR890700036A (ko) 비내 투여용 제제 및 그 제조방법
CA2211006A1 (en) Topically applied pharmaceutical composition, method of preparing it and its use
NO940111L (no) Farmasöytiske preparater inneholdene nanokapsler
GB9126209D0 (en) Drug formulations for parenteral use
NZ513810A (en) Compositions and methods for improved delivery of hydrophobic therapeutic agents
MX173607B (es) Antitranspirante cristalino y metodo para su preparacion
CA2091152A1 (en) Solid lipid particles, particles of bioactive agents and methods for the manfuacture and use thereof
KR960700039A (ko) β-시클로덱스트린 유도체 및 탄산 탈수효소 저해제로 이루어진 안과용 국소 투여 조성물(Topical Compositions for the Eye Comprising a β-cyclodextrin Derivative and a Carbonic Anhydrase Inhibitor)
AR011192A1 (es) Composiciones oftalmicas que comprenden una prostaglandina y el uso de los mismos en la preparacion de un medicamento para tratar glaucoma
NZ233153A (en) Moisturising vehicle for the topical application of vitamin a in acid form
GR3030528T3 (en) Viscoelastic compositions of fluorinated organic compounds
KR900005973A (ko) 사이클로스포린 안과용 조성물
EP0197987A1 (de) Verfahren zur herstellung von lösungen von umgekehrten mizellen.
EP1124535A1 (en) Preservative system for topically administrable pharmaceutical compositions containing a fatty acid/amino acid soap
CA2180480A1 (fr) Procede de preparation de liposomes sans utilisation de solvant organique
KR900013964A (ko) 활성형 비타민 d₃류 제제용 조성물 및 이를 함유하는 안정한 활성형 비타민 d₃류 제제의 제조방법
KR19980071702A (ko) 유제용 보존제 및 이를 함유한 유제
GB2303791A (en) Method of preparing a predetermined active agent stock solution for liposomal microencapsulation of active agents for agricultural uses
GB2105589A (en) Injectable suspensions containing maleic acid or a salt thereof as a stabilising agent
EP0123142B1 (de) Verfahren zur Stabilisierung von Hämatin
JPH09169642A (ja) テトラヒドロゾリン含有液剤
FI56486C (fi) Foerfarande foer framstaellning av en karbamid innehaollande farmaceutisk komposition till anvaendning foer utvaertes bruk pao maenniskohud

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19970116

Kind code of ref document: A1

Effective date: 19970116

FD2A Announcement of lapse in spain

Effective date: 20180806